| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Immunotherapies have recently emerged as a therapeutic option for patients with non-small cell lung cancer (NSCLC). Therapies have been approved for both first- and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression.
Immunotherapy test menu
Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific therapies. The specific PD-L1 clone, scoring method, and eligibility requirements depend on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor under consideration.
The FDA List of Cleared or Approved Companion Diagnostic Devices is frequently updated and provides current guidance for treatment indications and scoring.
Key testing
Highlights
In this month’s “Hot Topic,” Anja Roden, M.D., will discuss the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in Non-Small Cell Lung Carcinoma (NSCLC).